Last updated: April 24, 2026
What Is the Patent Landscape for JP2012506446 in Japan?
Which document is JP2012506446 and what does it cover?
JP2012506446 is a Japanese publication number for an international application entering Japan. The key scope and enforceable claims depend on the specific claim set of the Japanese publication (and any post-grant amendments), plus the family’s WO/PCT application claims and any national-phase prosecution outcomes in Japan.
This request cannot be completed accurately because the patent’s bibliographic data, claim text, and family members for JP2012506446 are not present in the provided material. Without the actual claim language, priority, assignee, and legal status, a complete scope-and-claims analysis would risk generating incorrect or fabricated patent coverage.
What is the practical patent landscape impact in Japan?
A reliable landscape requires at least the following, all of which must be drawn from the patent record and the publication text for JP2012506446:
- Claim-by-claim scope (independent and dependent claims, composition vs. method vs. use)
- Drug substance and/or drug product identity (active ingredient(s), salts, polymorphs, formulations)
- Key limitation types (dose ranges, routes, patient populations, biomarkers, manufacturing parameters)
- Family linkages (WO/PCT number, EP/US equivalents, earlier priority filings)
- Japan legal status (granted vs. pending, term extensions, lapses, withdrawals, invalidation risks)
- Position vs. competing families (overlapping active ingredient claims, formulation claims, crystal/polymorph claims, and method-of-treatment claims)
None of this can be produced without the underlying JP2012506446 record and its claim text.
What does a correct scope-and-claims map for JP2012506446 require?
A business-useful map must identify:
- Core claim category (product, process, method-of-treatment, use)
- Claim boundaries (what is included and excluded)
- Design-around pathways (alternative salts/crystals, different dosage regimens, different formulation architectures)
- Enforceability hooks in Japan (how the claims map to approval-relevant endpoints and labels)
- Cross-jurisdiction overlap (where the same claim language is asserted in other major markets, indicating likely strength)
This cannot be done from the publication number alone in a way that meets a hard accuracy standard.
Key Takeaways
- A full, accurate scope and claims analysis for JP2012506446 requires the actual Japanese claim set and bibliographic record for that specific publication.
- A landscape view in Japan must anchor on legal status and family claim overlap, which cannot be derived from the identifier alone.
- Providing a detailed patent landscape without the claim text would create a high risk of factual error.
FAQs
1) Does JP2012506446 automatically mean a granted Japanese patent?
No. Publication numbers do not confirm grant. Japan legal status must be checked via the patent register and publication/grant documents.
2) Are claims in Japan the same as the WO/PCT publication?
Not necessarily. Japan prosecution can narrow or clarify claim scope. The Japanese publication claim set must be analyzed directly.
3) Can the landscape change if there were claim amendments?
Yes. Amended claims can materially shift infringement risk and design-around options.
4) What are the most common “landscape drivers” for drug patents in Japan?
Typically: active ingredient claim language, salt/polymorph/crystal coverage, formulation claims, and method-of-use claim boundaries.
5) How is Japan infringement risk assessed for drug patents?
By mapping the marketed product and label claims to the specific Japanese claim elements (including product structure and method steps), not by the general topic of the technology.
References (APA)
[1] JP2012506446 (Japanese patent publication number) (bibliographic and claim text required for analysis).
